ICE Bioscience Posters

Download

Phosphodiesterases (PDEs) are enzymes that hydrolyze cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) into AMP and GMP, respectively. Inhibitors of PDEs allow the elevation of cAMP and cGMP which lead to a variety of cellular effects including airway smooth muscle relaxation and inhibition of cellular inflammation or of immune responses. PDE4 inhibitors are potent inhibitors of inflammation, and they have been approved for the treatment of inflammatory diseases ranging from arthritis to chronic obstructive pulmonary disease (COPD). In addition, PDE4 inhibitors are approved as oral or topical treatments for psoriasis and atopic dermatitis, respectively. As PDE4 is such an appealing clinical target for many additional non-dermatologic indications, additional research has continued to pursue strategies to widen the therapeutic index. Therefore, we have launched these integrated services for PDE4 screening platform from in vitro to in vivo, to get a comprehensive investigation of PDE4.